Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GE wants on the T-wave

This article was originally published in The Gray Sheet

Executive Summary

CMS accepts GE Healthcare's request Aug. 17 to consider national coverage of its Marquette modified moving average (MMA) microvolt T-wave alternans test. MTWA tests are used to risk stratify patients for cardioverter defibrillator implants. Based on lack of evidence, a March 2006 CMS coverage decision excludes the MMA method - cleared for risk stratification in 2003 - and only covers Cambridge Heart's HearTwave II test, which uses a proprietary spectral analysis algorithm (1"The Gray Sheet" March 27, 2006, p. 18). GE says studies published in 2007 show MMA's equivalence to the spectral method. CMS is accepting initial comments on the reconsideration until Sept. 17 and will issue a proposed decision by Feb. 17...

You may also be interested in...



Heart Rhythm Society, Doctors Oppose National Coverage Of GE’s MTWA Test

GE Healthcare and Cambridge Heart are squaring off over rival methods of microvolt T-wave alternans testing

Medicare In Brief

MTWA covered: Cambridge Heart receives national coverage for its Heartwave II Microvolt T-Wave Alternans test March 21. The non-invasive test can identify patients who are unlikely to benefit from an implantable cardioverter defibrillator. ICD manufacturers, who argued against coverage during the public comment period, fear that the final decision represents an attempt by CMS to cut Medicare costs by reducing the ICD candidate population. The final coverage determination echoes CMS' Dec. 21 proposed decision, which requires use of Cambridge Heart's patented analytic spectral algorithm, but does not mandate MTWA testing for a patient to be eligible for an ICD (1"The Gray Sheet" Jan. 2, 2006, p. 6). Because General Electric's Marquette T-Wave Alternans device relies on a different algorithm than Cambridge Heart's, CMS says that all local carriers covering GE's device must halt coverage until the firm applies for an NCD...

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel